FHTX · Foghorn Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| DECICCO CARL Chief Scientific Officer | ▲ Buy | Option Exercise | 362,707 Shares held | 12/9/2021 | View profile |
| KADOCH CIGALL | ▼ Sell | Gift | 295,000 Shares held | 12/14/2021 | View profile |
| Adrian Gottschalk Chief Executive Officer | ▼ Sell | Gift | 270,912 Shares held | 4/10/2026 | View profile |
| Bellon Steven F. Chief Scientific Officer | ▼ Sell | Open Market | 101,957 Shares held | 9/9/2024 | View profile |
| Cavalie Fanny Chief Strategy/Bus Ops Officer | ▼ Sell | Open Market | 75,992 Shares held | 3/11/2024 | View profile |
| GILL SIMBA | ▼ Sell | Gift | 34,061 Shares held | 9/13/2022 | View profile |
| Carlos Costa Chief People Officer | ▼ Sell | Open Market | 0 Shares held | 9/23/2024 | View profile |
| Agresta Samuel Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 8/16/2023 | View profile |
Transaction History
| Adrian Gottschalk | ▼ Sell | Gift | 59,208 | $0 | 4/10/2026 |
| Adrian Gottschalk | ▼ Sell | Gift | 59,208 | $0 | 4/10/2026 |
| Adrian Gottschalk | ▼ Sell | Gift | 47,497 | $0 | 4/9/2026 |
| Adrian Gottschalk | ▼ Sell | Gift | 47,497 | $0 | 4/9/2026 |
| Adrian Gottschalk | ▼ Sell | Gift | 300,000 | $0 | 4/25/2025 |
| Adrian Gottschalk | ▼ Sell | Gift | 300,000 | $0 | 4/25/2025 |
| Adrian Gottschalk | ▼ Sell | Gift | 197,906 | $0 | 4/9/2025 |
| Adrian Gottschalk | ▼ Sell | Gift | 197,906 | $0 | 4/9/2025 |
| Carlos Costa | ▲ Buy | Option Exercise | 857 | $3K | 9/23/2024 |
| Carlos Costa | ▼ Sell | Open Market | 857 | $9K | 9/23/2024 |
| Carlos Costa | ▲ Buy | Option Exercise | 35,756 | $133K | 9/20/2024 |
| Carlos Costa | ▼ Sell | Open Market | 35,756 | $359K | 9/20/2024 |
| Carlos Costa | ▲ Buy | Option Exercise | 11,574 | $43K | 9/18/2024 |
| Carlos Costa | ▼ Sell | Open Market | 11,574 | $116K | 9/18/2024 |
| Carlos Costa | ▼ Sell | Open Market | 10,272 | $103K | 9/17/2024 |
| Carlos Costa | ▲ Buy | Option Exercise | 10,272 | $38K | 9/17/2024 |
| Carlos Costa | ▲ Buy | Option Exercise | 400 | $1K | 9/16/2024 |
| Carlos Costa | ▼ Sell | Open Market | 400 | $4K | 9/16/2024 |
| Bellon Steven F. | ▼ Sell | Open Market | 20,000 | $190K | 9/9/2024 |
| Cavalie Fanny | ▼ Sell | Open Market | 11,000 | $72K | 3/11/2024 |
| Adrian Gottschalk | ▼ Sell | Gift | 63,000 | $0 | 8/17/2023 |
| Adrian Gottschalk | ▼ Sell | Gift | 63,000 | $0 | 8/17/2023 |
| Agresta Samuel | ▲ Buy | Option Exercise | 311,297 | $1.2M | 8/16/2023 |
| Agresta Samuel | ▼ Sell | Open Market | 311,297 | $2.6M | 8/16/2023 |
| Adrian Gottschalk | ▼ Sell | Gift | 300,000 | $0 | 5/26/2023 |
| Adrian Gottschalk | ▼ Sell | Gift | 300,000 | $0 | 5/26/2023 |
| Adrian Gottschalk | ▼ Sell | Gift | 4,371 | $0 | 2/17/2023 |
| Adrian Gottschalk | ▼ Sell | Gift | 4,371 | $0 | 2/17/2023 |
| Adrian Gottschalk | ▼ Sell | Other | 184,939 | $0 | 2/17/2023 |
| Adrian Gottschalk | ▼ Sell | Other | 184,939 | $0 | 2/17/2023 |
| Adrian Gottschalk | ▼ Sell | Other | 4,371 | $0 | 10/25/2022 |
| Adrian Gottschalk | ▼ Sell | Other | 4,371 | $0 | 10/25/2022 |
| Adrian Gottschalk | ▲ Buy | Option Exercise | 40,000 | $22K | 9/16/2022 |
| GILL SIMBA | ▼ Sell | Gift | 47,939 | $0 | 9/13/2022 |
| GILL SIMBA | ▲ Buy | Option Exercise | 82,000 | $60K | 9/12/2022 |
| Bellon Steven F. | ▲ Buy | Option Exercise | 1,858 | $7K | 8/11/2022 |
| Bellon Steven F. | ▲ Buy | Option Exercise | 675 | $493 | 5/25/2022 |
| Bellon Steven F. | ▲ Buy | Option Exercise | 3,717 | $14K | 5/25/2022 |
| Adrian Gottschalk | ▼ Sell | Gift | 123,479 | $0 | 2/10/2022 |
| Adrian Gottschalk | ▼ Sell | Gift | 123,479 | $0 | 2/10/2022 |
| KADOCH CIGALL | ▼ Sell | Gift | 333,333 | $0 | 12/14/2021 |
| DECICCO CARL | ▲ Buy | Option Exercise | 104,310 | $388K | 12/9/2021 |
| Adrian Gottschalk | ▲ Buy | Option Exercise | 23,000 | $12K | 8/20/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.